Evaluation of the Effect of Mirikizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients With Moderate-to-Severe Plaque Psoriasis
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Oct 2019
Price : $35 *
At a glance
- Drugs Mirikizumab (Primary) ; Caffeine; Dextromethorphan; Midazolam; Omeprazole; Warfarin
- Indications Plaque psoriasis
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 03 Oct 2019 Planned End Date changed from 22 Sep 2019 to 28 Oct 2019.
- 03 Oct 2019 Planned primary completion date changed from 22 Sep 2019 to 28 Oct 2019.
- 16 Aug 2019 Status changed from recruiting to active, no longer recruiting.